Existing severe osteoporotic vertebral fractures in elderly Chinese males were only weakly associated with higher further vertebral fracture risk at year-4 follow-up

2020 ◽  
Vol 31 (8) ◽  
pp. 1593-1594 ◽  
Author(s):  
Y.X.J. Wáng ◽  
N. Che-Nordin ◽  
J.C.S. Leung ◽  
T.C.Y. Kwok
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Vertebral Fractures ◽  
Osteoporotic Vertebral Fractures ◽  
Vertebral Fracture Risk ◽  
Elderly Chinese

scholarly journals Type 2 Diabetes Mellitus and Vertebral Fracture Risk

2021 ◽  
Author(s):  
Fjorda Koromani ◽  
Samuel Ghatan ◽  
Mandy van Hoek ◽  
M. Carola Zillikens ◽  
Edwin H. G. Oei ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Vertebral Fractures ◽  
Bone Fragility ◽  
Marrow Fat ◽  
Systematic Screening ◽  
Published Evidence ◽  
Vertebral Fracture Risk

Abstract Purpose of Review The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus. Recent Findings Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Summary Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

2004 ◽  
Vol 22 (5) ◽  
pp. 462-468 ◽  
Author(s):  
Kazuhiro Kushida ◽  
Masataka Shiraki ◽  
Toshitaka Nakamura ◽  
Hideaki Kishimoto ◽  
Hirotoshi Morii ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Japanese Women ◽  
Follow Up Study ◽  
Vertebral Fracture Risk

scholarly journals Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Naohisa Miyakoshi ◽  
Akira Horikawa ◽  
Yoichi Shimada
Keyword(s):  
Vertebral Fracture ◽  
Fracture Healing ◽  
Clinical Experience ◽  
Vertebral Body ◽  
Vertebral Fractures ◽  
Surgical Intervention ◽  
Osteoporotic Vertebral Fracture ◽  
Kyphosis Angle ◽  
Osteoporotic Vertebral Fractures

Osteoporotic vertebral fractures usually heal with kyphotic deformities with subsidence of the vertebral body when treated conservatively. Corrective vertebral union using only antiosteoporotic pharmacotherapy without surgical intervention has not been reported previously. An 81-year-old female with osteoporosis presented with symptomatic fresh L1 vertebral fracture with intravertebral cleft. Segmental vertebral kyphosis angle (VKA) at L1 was 20° at diagnosis. Once-weekly teriparatide administration, hospitalized rest, and application of a thoracolumbosacral orthosis alleviated symptoms within 2 months. Corrective union of the affected vertebra was obtained with these treatments. VKA at 2 months after injury was 8° (correction, 12°) and was maintained as of the latest follow-up at 7 months. Teriparatide has potent bone-forming effects and has thus been expected to enhance fracture healing. Based on the clinical experience of this case, teriparatide may have the potential to allow correction of unstable vertebral fractures without surgical intervention.

scholarly journals Parathyroid Hormone Injection Versus Vertebroplasty in the Treatment of Osteoporotic Vertebral Fracture in Old Age: A Retrospective Study of 58 Female Patients

2020 ◽  
Author(s):  
Incheol Kook ◽  
Byeong-Jik Kang ◽  
Ye-Soo Park
Keyword(s):  
Parathyroid Hormone ◽  
Retrospective Study ◽  
Vertebral Fracture ◽  
Conservative Treatment ◽  
Vertebral Fractures ◽  
Cement Leakage ◽  
Osteoporotic Vertebral Fracture ◽  
Group I ◽  
Osteoporotic Vertebral Fractures

Abstract Background: While the indications of parathyroid hormone (PTH) in osteoporosis prevention and management have been established, its indications in the treatment of osteoporotic vertebral fractures remain unknown. This study aimed to compare the effects of intervention (percutaneous vertebroplasty followed by anti-resorptive agents) and conservative treatment (PTH administration) in patients with osteoporotic vertebral fractures, as well as to investigate the optimal duration of PTH administration. Methods: A retrospective study was conducted using data of patients treated for osteoporotic vertebral fractures between January 2015 and November 2019. Treatment was selected based on the patient’s age, comorbidities, and patient’s preference after explaining the expected advantages and disadvantages of each treatment. Group C was administered PTH injections once weekly, whereas Group I underwent vertebroplasty followed by the administration of anti-resorptive agents. Radiological and clinical parameters were analyzed between two groups.Results: This study enrolled 58 patients (77 vertebrae). Group C included 24 patients (38 vertebrae) with average age of 77.50 ± 7.19 years (range, 65–85 years), average bone mineral density (BMD) of −3.39 ± 0.86 (range, −2.5 to −5.8), average follow-up period of 27.47 ± 7.60 weeks (range, 12–49 weeks). Group I included 34 patients (39 vertebrae) with an average age of 76.20 ± 8.67 years (range, 65–92 years), average BMD of −3.35 ± 0.91 (range, −2.5 to −5.1), average follow-up period of 30.82 ± 10.95 weeks (range, 16–59 weeks). There was no significant difference between the two groups in initial demographic, clinical and radiographic parameters. Group I showed significantly better clinical and radiological outcome during the last follow-up. Regarding side effects in Group C, two cases of dizziness (8.3%), nausea and vomiting (8.3%) were reported. In Group I, cement leakage was found in 26 vertebrae (66.7%), and cement leakage complications were observed in four patients (11.8%). Conclusion: Conservative treatment using PTH injection demonstrated slower pain relief and lesser suppression of vertebral height loss than vertebroplasty. However, PTH injection demonstrated a lower risk of procedure-related complications. The patient’s age, preference, and general condition with respect to the procedure’s risk should be considered when determining treatment options for osteoporotic vertebral fracture in old age.

scholarly journals Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

2005 ◽  
Vol 23 (1) ◽  
pp. 95-95
Author(s):  
Kazuhiro Kushida ◽  
Masataka Shiraki ◽  
Toshitaka Nakamura ◽  
Hideaki Kishimoto ◽  
Hirotoshi Morii ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Japanese Women ◽  
Follow Up Study ◽  
Vertebral Fracture Risk

scholarly journals Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial

2013 ◽  
Vol 29 (3) ◽  
pp. 195-203 ◽  
Author(s):  
Toshitsugu Sugimoto ◽  
Masataka Shiraki ◽  
Tetsuo Nakano ◽  
Hideaki Kishimoto ◽  
Masako Ito ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Follow Up Study ◽  
Vertebral Fracture Risk ◽  
Efficacy Research

Elderly men have much lower vertebral fracture risk than elderly women even at advanced age: the MrOS and MsOS (Hong Kong) year 14 follow-up radiology results

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Yì Xiáng J. Wáng ◽  
Nazmi Che-Nordin ◽  
Jason C. S. Leung ◽  
Blanche Wai Man Yu ◽  
James F. Griffith ◽  
...  
Keyword(s):  
Hong Kong ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Elderly Women ◽  
Advanced Age ◽  
Elderly Men ◽  
Vertebral Fracture Risk

scholarly journals Time Course of Acute Vertebral Fractures: A Prospective Multicenter Cohort Study

2021 ◽  
Vol 10 (24) ◽  
pp. 5961
Author(s):  
Hiroyuki Inose ◽  
Tsuyoshi Kato ◽  
Shinichi Shirasawa ◽  
Shinji Takahashi ◽  
Masatoshi Hoshino ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Low Back Pain ◽  
Back Pain ◽  
Vertebral Fracture ◽  
Vertebral Fractures ◽  
Low Back ◽  
Osteoporotic Vertebral Fractures ◽  
Significant Difference

To date, it is still unclear how fresh osteoporotic vertebral fractures (OVFs) affect the patient’s quality of life and low back pain during a follow-up period of more than 1 year. In the previous trial, women with fresh OVF were randomized to rigid or soft brace for 12 weeks, then both groups were followed for the subsequent 48 weeks. In women completing this trial at our affiliated hospitals, we conducted a follow-up study to investigate the long-term course of an acute vertebral fracture in terms of pain and quality of life. When comparing visual analog scale scores for low back pain and European Quality of Life-5 Dimensions Questionnaire scores between consecutive time points, a significant difference was found between 0 and 12 weeks, but not between 12 and 48 weeks or between 48 weeks and final follow-up. A total 25% had residual low back pain at the final follow-up. A stepwise logistic regression analysis identified age and previous vertebral fracture as predictors of residual low back pain at the final follow-up. Therefore, the degree of low back pain and impairment of the quality of life improved by 12 weeks after injury and did not change thereafter until a mean follow-up of 5.3 years.

scholarly journals Interaction between Vitamin D Receptor Genotype and Estrogen Receptor α Genotype Influences Vertebral Fracture Risk

2003 ◽  
Vol 88 (8) ◽  
pp. 3777-3784 ◽  
Author(s):  
E. M. Colin ◽  
A. G. Uitterlinden ◽  
J. B. J. Meurs ◽  
A. P. Bergink ◽  
M. Van De Klift ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Mineral Density ◽  
Vdr Gene ◽  
Length Polymorphisms ◽  
Osteoporotic Vertebral Fractures ◽  
Vertebral Fracture Risk ◽  
Haplotype 1 ◽  
Restriction Fragment Length

In view of the interactions of vitamin D and the estrogen endocrine system, we studied the combined influence of polymorphisms in the estrogen receptor (ER) α gene and the vitamin D receptor (VDR) gene on the susceptibility to osteoporotic vertebral fractures in 634 women aged 55 yr and older. Three VDR haplotypes (1, 2, and 3) of the BsmI, ApaI, and TaqI restriction fragment length polymorphisms and three ERα haplotypes (1, 2, and 3) of the PvuII and XbaI restriction fragment length polymorphisms were identified. We captured 131 nonvertebral and 85 vertebral fracture cases during a mean follow-up period of 7 yr. ERα haplotype 1 was dose-dependently associated with increased vertebral fracture risk (P < 0.001) corresponding to an odds ratio of 1.9 [95% confidence interval (CI), 0.9–4.1] per copy of the risk allele. VDR haplotype 1 was overrepresented in vertebral fracture cases. There was a significant interaction (P = 0.01) between ERα haplotype 1 and VDR haplotype 1 in determining vertebral fracture risk. The association of ERα haplotype 1 with vertebral fracture risk was only present in homozygous carriers of VDR haplotype 1. The risk of fracture was 2.5 (95% CI, 0.6–9.9) for heterozygous and 10.3 (95% CI, 2.7–40) for homozygous carriers of ERα haplotype 1. These associations were independent of bone mineral density. In conclusion, interaction between ERα and VDR gene polymorphisms leads to increased risk of osteoporotic vertebral fractures in women, largely independent of bone mineral density.

Sign in / Sign up

Export Citation Format

Share Document